nystatin-a1 and Acquired-Immunodeficiency-Syndrome

nystatin-a1 has been researched along with Acquired-Immunodeficiency-Syndrome* in 6 studies

Trials

2 trial(s) available for nystatin-a1 and Acquired-Immunodeficiency-Syndrome

ArticleYear
Evaluation and treatment of oral candidiasis in HIV/AIDS patients in Enugu, Nigeria.
    Oral and maxillofacial surgery, 2008, Volume: 12, Issue:2

    Oral candidiasis is one of the common diseases seen in HIV/AIDS patients. It is rare if CD4+ cell counts are above 500 microl. Outbreaks are more common as the count drops to 100 microl. It may be more difficult to treat when CD4+ cell counts fall below 50 microl.. A retrospective review of 112 HIV/AIDS patients with lesions in the mouth, head, and neck seen at the oral and maxillofacial surgery units of two public hospitals in eastern Nigeria was carried out between 2000 and 2003. The focus was on oral candidiasis patients. Twenty-nine of these patients, made up of 11 males and 18 females, had oral candidiasis. To compare the action of two drugs, namely, nystatin (a topical antifungal drug) and ketoconazole (a systemic antifungal drug), we treated 15 of the patients with nystatin in the first 2 years and the remaining 14 with ketoconazole in the following 2 years.. Amongst the 15 patients treated with topical drugs, 7 (46.7%) had complete remission, 2 (13.3%) had partial response, 4 (26.7%) remained stationary, and 2 (13.3%) died. Out of the 14 cases treated with systemic drugs, 11 (78.6%) had complete remission, 2 (14.3%) had partial response, and 1 (7.1%) died.

    Topics: Acquired Immunodeficiency Syndrome; Administration, Topical; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; Humans; Immunocompromised Host; Ketoconazole; Male; Middle Aged; Mouthwashes; Nystatin; Treatment Outcome

2008
Gentian violet, ketoconazole and nystatin in oropharyngeal and esophageal candidiasis in Zairian AIDS patients.
    Annales de la Societe belge de medecine tropicale, 1992, Volume: 72, Issue:1

    A randomized un-blinded study on the treatment of oropharyngeal and esophageal candidiasis was conducted in Kinshasa (Zaire), among 141 inpatients with AIDS and oropharyngeal candidiasis, of whom 136 also had esophageal candidiasis. The study compared the efficacy of gentian violet mouth washes (1.5 ml 0.5% aqueous solution b.i.d.), oral ketoconazole (200 mg/day, after a meal) and nystatin mouth washes (200.000 U oral suspension q.i.d.). Patients treated with mouth washes swallowed their medication after mouth washing. Patients enrolled in this study had a very high mortality (probability of death: 41.6% after 14 days). After 14 days, 72 patients could be evaluated. At that time, oropharyngeal lesions had disappeared in similar proportions of patients treated with gentian violet (11/26, 42%) and ketoconazole (10/23, 43%), and in a lower proportion of patients treated with nystatin (2/23, 9%; p less than 0.05). In esophageal candidiasis, ketoconazole seemed more efficient than both other treatments: esophageal lesions had disappeared in 5 (24%) of the 21 patients on ketoconazole, compared to less than 10% of patients on both other treatments (p = 0.07). The suboptimal results observed with all 3 treatments could be explained by the profound immunosuppression of patients enrolled in the study. This study suggests that gentian violet is effective treatment for oropharyngeal candidiasis. As it is very cheap (0.5 US$/treatment course in Kinshasa), we suggest that its use should be assessed in larger studies.

    Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis, Oral; Democratic Republic of the Congo; Female; Gentian Violet; Humans; Ketoconazole; Male; Nystatin

1992

Other Studies

4 other study(ies) available for nystatin-a1 and Acquired-Immunodeficiency-Syndrome

ArticleYear
Drugs for AIDS and associated infections.
    The Medical letter on drugs and therapeutics, 1995, Oct-13, Volume: 37, Issue:959

    Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiprotozoal Agents; Antiviral Agents; Atovaquone; Candidiasis, Oral; Clindamycin; Clotrimazole; Cryptosporidiosis; Cytomegalovirus Infections; Dapsone; Didanosine; Drug Combinations; Drug Therapy, Combination; Fluconazole; Flucytosine; Folic Acid Antagonists; Foscarnet; Glucuronates; Herpes Simplex; Herpes Zoster; Humans; Isoniazid; Itraconazole; Ketoconazole; Lamivudine; Mycobacterium avium-intracellulare Infection; Naphthoquinones; Nystatin; Pentamidine; Pneumocystis Infections; Pneumonia, Pneumocystis; Prednisone; Primaquine; Reverse Transcriptase Inhibitors; Stavudine; Syphilis; Toxoplasmosis; Trimetrexate; Tuberculosis; Zalcitabine; Zidovudine

1995
Alternative therapies for major aphthous ulcers in AIDS patients.
    Journal of the American Dental Association (1939), 1992, Volume: 123, Issue:7

    Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Administration, Topical; Adult; Anti-Inflammatory Agents; Humans; Hydrocortisone; Levamisole; Male; Middle Aged; Mouthwashes; Nystatin; Pentamidine; Stomatitis, Aphthous; Tetracycline; Triamcinolone; Zidovudine

1992
AIDS and oropharyngeal candidiasis.
    Israel journal of dental sciences, 1989, Volume: 2, Issue:3

    Oropharyngeal candidiasis occurred in a previously healthy young Israeli homosexual male. Additional symptoms included persistent diarrhea, weight loss, fever, generalized lymphadenopathy and peripheral neuropathy. Immunologic studies revealed lymphopenia with reversed T-helper/T-suppressor cells ratio and antibodies to human immunodeficiency virus, all compatible with the diagnosis of subclinical AIDS. Repeated courses of antimonilial treatment failed to eradicate the oropharyngeal lesions. The clinical picture of AIDS, particularly its oral manifestations, is described. The diagnostic and prognostic implications of oropharyngeal candidiasis as a presenting sign of the disease are discussed. In addition, precautionary measures that should be taken when treating persons infected with HIV are described.

    Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis, Oral; Humans; Male; Nystatin

1989
Oral presentation of undiagnosed and asymptomatic human immunodeficiency virus infection: report of a case.
    The Journal of the Michigan Dental Association, 1987, Volume: 69, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Candidiasis, Oral; Humans; Male; Nystatin

1987